BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 11698703)

  • 1. Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains.
    Goudsmit J; Weverling GJ; van der Hoek L; de Ronde A; Miedema F; Coutinho RA; Lange JM; Boerlijst MC
    AIDS; 2001 Nov; 15(17):2293-301. PubMed ID: 11698703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transmission of zidovudine resistant strains of HIV-1: the first wave.
    Blower S
    AIDS; 2001 Nov; 15(17):2317-8. PubMed ID: 11698706
    [No Abstract]   [Full Text] [Related]  

  • 3. Occurrence of HIV-1 reverse transcriptase gene mutation at codon 215 in HIV-infected infants.
    Kamkamidze G; Sullivan T; Charbonneau T
    J Clin Virol; 2001 Aug; 22(1):143-8. PubMed ID: 11418362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A fossil record of zidovudine resistance in transmitted isolates of HIV-1.
    Kuritzkes DR
    Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13485-7. PubMed ID: 11717419
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zidovudine genotypic resistance in HIV-1-infected newborns in the French perinatal cohort.
    Masquelier B; Chaix ML; Burgard M; Lechenadec J; Doussin A; Simon F; Cottalorda J; Izopet J; Tamalet C; Douard D; Fleury H; Mayaux MJ; Blanche S; Rouzioux C;
    J Acquir Immune Defic Syndr; 2001 Jun; 27(2):99-104. PubMed ID: 11404530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy.
    Middleton T; Smith D; Larder B; Law M; Birch C
    HIV Clin Trials; 2001; 2(6):445-52. PubMed ID: 11742431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type-1 nucleoside reverse-transcriptase inhibitors.
    Venturi G; Romano L; Catucci M; Riccio ML; De Milito A; Gonnelli A; Rubino M; Valensin PE; Zazzi M
    Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):274-82. PubMed ID: 10385016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team.
    Rey D; Hughes M; Pi JT; Winters M; Merigan TC; Katzenstein DA
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar; 17(3):203-8. PubMed ID: 9495218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
    J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
    Ross L; Johnson M; Graham N; Shaefer M; St Clair M
    J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
    Kovacs A; Cowles MK; Britto P; Capparelli E; Fowler MG; Moye J; McIntosh K; Rathore MH; Pitt J; Husson RN
    Pediatr Infect Dis J; 2005 Jun; 24(6):503-9. PubMed ID: 15933559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
    Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
    AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
    J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies.
    Maguire M; Gartland M; Moore S; Hill A; Tisdale M; Harrigan R; Kleim JP
    AIDS; 2000 Jun; 14(9):1195-201. PubMed ID: 10894284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective vertical transmission of HIV-1 antiretroviral resistance mutations.
    Colgrove RC; Pitt J; Chung PH; Welles SL; Japour AJ
    AIDS; 1998 Dec; 12(17):2281-8. PubMed ID: 9863870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
    Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC;
    AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of the T215Y mutation in human immunodeficiency virus type 1-infected pregnant women in a New York cohort, 1995--1999.
    Sitnitskaya Y; Rochford G; Rigaud M; Essajee S; Pollack H; Krasinski K; Borkowsky W
    Clin Infect Dis; 2001 Jul; 33(1):e3-7. PubMed ID: 11389511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 genotypic zidovudine drug resistance and the risk of maternal--infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group.
    Welles SL; Pitt J; Colgrove R; McIntosh K; Chung PH; Colson A; Lockman S; Fowler MG; Hanson C; Landesman S; Moye J; Rich KC; Zorrilla C; Japour AJ
    AIDS; 2000 Feb; 14(3):263-71. PubMed ID: 10716502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.